Information on 
Informationen zu 
Informaciones sobre
A propos du
Informazioni suAbout Us / Management / Experience
Although a young company, SpePharm, through its founding management team, has a proven track record of successful development, registration, and/or commercialization of quality therapeutic products in supportive care, oncology & hematology, and orphan diseases. These products include:
- droperidol and dolasetron for post-operative nausea & vomiting
- milameline (muscarinic agonist) for AZ disease
- dolasetron and granisetron for chemotherapy-induced nausea & vomiting
- teicoplanin for severe Gram-positive infections
- cefotaxime (3rd GC) for severe infections
- oxaliplatin for colorectal cancer
- lomustine [CCNU] - for multiple solid tumors (brain tumors) and hematology
- amsacrine for acute leukemia
- altretamine for ovarian and lung cancer
- buserelin, nilutamide and triptorelin for advanced prostate cancer
- purified immunoglobulins for various auto-immune diseases
- hydroxyurea for sickle-cell disease
- recombinant gonadotropins for fertility treatments
The management team brings a wealth of collective experience in the pharmaceutical industry to the activities of SpePharm. This includes past experience in the creation and management of specialty pharmaceutical companies and handling their products. The team is therefore well versed in the sensitive areas of pricing, tendering and the pan-European marketing of hospital products.